Search

Your search keyword '"M. Dror"' showing total 191 results
Start Over Author "M. Dror" Search Limiters Peer Reviewed
191 results on '"M. Dror"'

1. Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926

Author

Dahl, Douglas M., Rodgers, Joseph P., Shipley, William U., Michaelson, M. Dror, Wu, Chin-Lee, Parker, William, Jani, Ashesh B., Cury, Fabio L., Hudes, Richard S., Michalski, Jeff M., Hartford, Alan C., Song, Daniel, Citrin, Deborah E., Karrison, Theodore G., Sandler, Howard M., Feng, Felix Y., and Efstathiou, Jason A.

Published
2024
Full Text
View/download PDF

3. Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study

Author

Allaf, Mohamad E, Kim, Se-Eun, Master, Viraj, McDermott, David F, Harshman, Lauren C, Cole, Suzanne M, Drake, Charles G, Signoretti, Sabina, Akgul, Mahmut, Baniak, Nicholas, Li-Ning, Elsa, Palmer, Matthew B, Emamekhoo, Hamid, Adra, Nabil, Kaimakliotis, Hristos, Ged, Yasser, Pierorazio, Phillip M, Abel, E Jason, Bilen, Mehmet A, Ogan, Kenneth, Moon, Helen H, Ramaswamy, Krishna A, Singer, Eric A, Mayer, Tina M, Lohrey, Jay, Margulis, Vitaly, Gills, Jessie, Delacroix, Scott E, Waples, Mark J, James, Andrew C, Wang, Peng, Choueiri, Toni, Michaelson, M Dror, Kapoor, Anil, Heng, Daniel Y, Shuch, Brian, Leibovich, Bradley C, Lara, Primo N, Manola, Judith, Maskens, Deborah, Battle, Dena, Uzzo, Robert, Bratslavsky, Gennady, Haas, Naomi B, and Carducci, Michael A

Published
2024
Full Text
View/download PDF

5. Long-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524—A Phase 1/2 Trial of Paclitaxel + Trastuzumab with Daily Radiation or Paclitaxel Alone with Daily Irradiation

Author

Dahl, Douglas M., Karrison, Theodore G., Michaelson, M. Dror, Pham, Huong T., Wu, Chin-Lee, Swanson, Gregory P., Shipley, William U., Vuky, Jacqueline, Lee, R. Jeffrey, Zietman, Anthony L., Souhami, Luis, Chang, Brian K., Deming, Richard L., Ellerton, John A., Sandler, Howard M., Rodgers, Joseph P., Feng, Felix Y., and Efstathiou, Jason A.

Published
2024
Full Text
View/download PDF

9. Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma

Author

McGregor, Bradley A., Xie, Wanling, Adib, Elio, Stadler, Walter M., Zakharia, Yousef, Alva, Aijai, Michaelson, M. Dror, Gupta, Shilpa, Lam, Elaine T., Farah, Subrina, Nassar, Amin H., Wei, Xiao X., Kilbridge, Kerry L., Harshman, Lauren, Signoretti, Sabina, Sholl, Lynette, Kwiatkowski, David J., McKay, Rana R., and Choueiri, Toni K.

Published
2022
Full Text
View/download PDF

10. Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis

Author

Alexandre R Zlotta, Leslie K Ballas, Andrzej Niemierko, Katherine Lajkosz, Cynthia Kuk, Gus Miranda, Michael Drumm, Andrea Mari, Ethan Thio, Neil E Fleshner, Girish S Kulkarni, Michael A S Jewett, Robert G Bristow, Charles Catton, Alejandro Berlin, Srikala S Sridhar, Anne Schuckman, Adam S Feldman, Matthew Wszolek, Douglas M Dahl, Richard J Lee, Philip J Saylor, M Dror Michaelson, David T Miyamoto, Anthony Zietman, William Shipley, Peter Chung, Siamak Daneshmand, and Jason A Efstathiou

Subjects
Oncology
Published
2023
Full Text
View/download PDF

12. Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes

Author

Nuzzo, Pier Vitale, Berchuck, Jacob E., Korthauer, Keegan, Spisak, Sandor, Nassar, Amin H., Abou Alaiwi, Sarah, Chakravarthy, Ankur, Shen, Shu Yi, Bakouny, Ziad, Boccardo, Francesco, Steinharter, John, Bouchard, Gabrielle, Curran, Catherine R., Pan, Wenting, Baca, Sylvan C., Seo, Ji-Heui, Lee, Gwo-Shu Mary, Michaelson, M. Dror, Chang, Steven L., Waikar, Sushrut S., Sonpavde, Guru, Irizarry, Rafael A., Pomerantz, Mark, De Carvalho, Daniel D., Choueiri, Toni K., and Freedman, Matthew L.

Published
2020
Full Text
View/download PDF

13. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update

Author

Choueiri, Toni K., Hessel, Colin, Halabi, Susan, Sanford, Ben, Michaelson, M. Dror, Hahn, Olwen, Walsh, Meghara, Olencki, Thomas, Picus, Joel, Small, Eric J., Dakhil, Shaker, Feldman, Darren R., Mangeshkar, Milan, Scheffold, Christian, George, Daniel, and Morris, Michael J.

Published
2018
Full Text
View/download PDF

17. Phase II Study of Cabozantinib in Patients With Bone Metastasis

Author

Edwin Choy, Gregory M Cote, M Dror Michaelson, Lori Wirth, Justin F Gainor, Alona Muzikansky, Lecia V Sequist, Ryan J Sullivan, Panagiotis M Fidias, Alice Shaw, and Rebecca S Heist

Subjects
Cancer Research, Oncology, Pyridines, Humans, Anilides, Bone Neoplasms, Sarcoma, Neoplasm Metastasis
Abstract

Bone metastases are often difficult to manage as they can be symptomatic and skeletal-related events (SREs) can contribute to significant morbidity and declines in performance status. We sought to identify a novel medical treatment for bone metastasis by testing the safety and efficacy of cabozantinib in patients with bone metastasis arising from non-breast, non-prostate, malignant solid tumors. Patients were administered cabozantinib as an oral drug starting at 60 mg per day and radiologic measurements were performed at baseline and every 8 weeks. Thirty-seven patients were enrolled. No SREs were observed throughout the study. Twenty patients had disease measurable by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Four of 20 had a partial response by RECIST. An additional 12 patients had some decrease in tumor burden with nine of these having a decrease in tumor burden of at least 10% by RECIST. Six of the patients with at least a minor response had sarcoma. Sixteen patients had biomarkers of bone turnover measured before and after treatment. Most of these patients demonstrated decrease in urine and serum N-telopeptide and serum C-telopeptide. However, these changes in biomarkers of bone turnover did not correlate with radiographic changes measured by RECIST. This study demonstrates clinical activity and safety for cabozantinib in heavily pretreated patients with bone metastasis and shows activity for cabozantinib in patients with metastatic sarcoma.

Published
2022
Full Text
View/download PDF

20. Treatment sequences for advanced renal cell carcinoma: A health economic assessment.

Author

Baris Deniz, Apoorva Ambavane, Shuo Yang, Arman Altincatal, Justin Doan, Sumati Rao, and M Dror Michaelson

Subjects
Medicine, Science
Abstract

ObjectiveAdvanced renal cell carcinoma (RCC) is commonly treated with vascular endothelial growth factor or mammalian target of rapamycin inhibitors. As new therapies emerge, interest grows in gaining a deeper understanding of treatment sequences. Recently, we developed a patient-level, discretely integrated condition event (DICE) simulation to estimate survival and lifetime costs for various cancer therapies, using a US payer perspective. Using this model, we explored the impact of treatments such as nivolumab and cabozantinib, and compared the clinical outcomes and cost consequences of commonly used treatment algorithms for patients with advanced RCC.MethodsIncluded treatment sequences were pazopanib or sunitinib as first-line treatment, followed by nivolumab, cabozantinib, axitinib, pazopanib or everolimus. Efficacy inputs were derived from the CheckMate 025 trial and a network meta-analysis based on available literature. Safety and cost data were obtained from publicly available sources or literature.ResultsBased on our analysis, the average cost per life-year (LY) was lowest for sequences including nivolumab (sunitinib → nivolumab, $75,268/LY; pazopanib → nivolumab, $84,459/LY) versus axitinib, pazopanib, everolimus and cabozantinib as second-line treatments. Incremental costs per LY gained were $49,592, $73,927 and $30,534 for nivolumab versus axitinib, pazopanib and everolimus-containing sequences, respectively. The model suggests that nivolumab offers marginally higher life expectancy at a lower cost versus cabozantinib-including sequences.ConclusionTreatment sequences using nivolumab in the second-line setting are less costly compared with sequential use of targeted agents. In addition to efficacy and safety data, cost considerations may be taken into account when considering treatment algorithms for patients with advanced RCC.

Published
2019
Full Text
View/download PDF

23. Dana-Farber Cancer Institute/Mass General Brigham Fellowship Response to the COVID-19 Pandemic

Author

Annemarie E. Fogerty, Robert M Stern, Aric Parnes, Ann S. LaCasce, Erica L. Mayer, Ryan D. Nipp, and M. Dror Michaelson

Subjects
Coronavirus disease 2019 (COVID-19), Distancing, education, Graduate medical education, MEDLINE, 03 medical and health sciences, 0302 clinical medicine, Overall response rate, Neoplasms, Pandemic, Humans, 030212 general & internal medicine, Fellowships and Scholarships, Pandemics, Medical education, SARS-CoV-2, Oncology (nursing), Health Policy, Dana-Farber Cancer Institute, COVID-19, Hematology, Direct feedback, United States, Oncology, Care Delivery Reviews, 030220 oncology & carcinogenesis, Psychology
Abstract

The coronavirus disease (COVID)-19 pandemic has affected graduate medical education training programs, including hematology-oncology fellowship programs, both across the United States and abroad. Within the Dana-Farber Cancer Institute/Mass General Brigham hematology-oncology fellowship program, fellowship leadership had to quickly reorganize the program's clinical, educational, and research structure to minimize the risk of COVID-19 spread to our patients and staff, allow fellows to assist in the care of patients with COVID-19, maintain formal didactics despite physical distancing, and ensure the mental and physical well-being of fellows. Following the first wave of patients with COVID-19, we anonymously surveyed the Dana-Farber Cancer Institute/Mass General Brigham first-year fellows to explore their perceptions regarding what the program did well and what could have been improved in the COVID-19 response. In this article, we present the feedback from our fellows and the lessons we learned as a program from this feedback. To our knowledge, this represents the first effort in the hematology-oncology literature to directly assess a hematology-oncology program's overall response to COVID-19 through direct feedback from fellows.

Published
2021
Full Text
View/download PDF

24. Application of dynamic modeling for survival estimation in advanced renal cell carcinoma.

Author

Baris Deniz, Arman Altincatal, Apoorva Ambavane, Sumati Rao, Justin Doan, Bill Malcolm, M Dror Michaelson, and Shuo Yang

Subjects
Medicine, Science
Abstract

OBJECTIVE:In oncology, extrapolation of clinical outcomes beyond trial duration is traditionally achieved by parametric survival analysis using population-level outcomes. This approach may not fully capture the benefit/risk profile of immunotherapies due to their unique mechanisms of action. We evaluated an alternative approach-dynamic modeling-to predict outcomes in patients with advanced renal cell carcinoma. We compared standard parametric fitting and dynamic modeling for survival estimation of nivolumab and everolimus using data from the phase III CheckMate 025 study. METHODS:We developed two statistical approaches to predict longer-term outcomes (progression, treatment discontinuation, and survival) for nivolumab and everolimus, then compared these predictions against follow-up clinical trial data to assess their proximity to observed outcomes. For the parametric survival analyses, we selected a probability distribution based on its fit to observed population-level outcomes at 14-month minimum follow-up and used it to predict longer-term outcomes. For dynamic modeling, we used a multivariate Cox regression based on patient-level data, which included risk scores, and probability and duration of response as predictors of longer-term outcomes. Both sets of predictions were compared against trial data with 26- and 38-month minimum follow-up. RESULTS:Both statistical approaches led to comparable fits to observed trial data for median progression, discontinuation, and survival. However, beyond the trial duration, mean survival predictions differed substantially between methods for nivolumab (30.8 and 51.5 months), but not everolimus (27.2 and 29.8 months). Longer-term follow-up data from CheckMate 025 and phase I/II studies resembled dynamic model predictions for nivolumab. CONCLUSIONS:Dynamic modeling can be a good alternative to parametric survival fitting for immunotherapies because it may help better capture the longer-term benefit/risk profile and support health-economic evaluations of immunotherapies.

Published
2018
Full Text
View/download PDF

28. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

Author

Rini, Brian I, Escudier, Bernard, Tomczak, Piotr, Kaprin, Andrey, Szczylik, Cezary, Hutson, Thomas E, Michaelson, M Dror, Gorbunova, Vera A, Gore, Martin E, Rusakov, Igor G, Negrier, Sylvie, Ou, Yen-Chuan, Castellano, Daniel, Lim, Ho Yeong, Uemura, Hirotsugu, Tarazi, Jamal, Cella, David, Chen, Connie, Rosbrook, Brad, Kim, Sinil, and Motzer, Robert J

Published
2011
Full Text
View/download PDF

29. Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma.

Author

Motzer, Robert J., Hutson, Thomas E., Tomczak, Piotr, Michaelson, M. Dror, Bukowski, Ronald M., Oudard, Stéphane, Negrier, Sylvie, Szczylik, Cezary, Pili, Roberto, Bjarnason, Georg A., Garcia-del-Muro, Xavier, Sosman, Jeffrey A., Solska, Ewa, Wilding, George, Thompson, John A., Kim, Sindy T., Chen, Isan, Huang, Xin, and Figlin, Robert A.

Published
2023
Full Text
View/download PDF

31. Clinical and economic outcomes of treatment sequences for intermediate- to poor-risk advanced renal cell carcinoma

Author

Sumati Rao, Anshul Shah, Apoorva Ambavane, David F. McDermott, Meredith M. Regan, M. Dror Michaelson, Shuo Yang, and Michael B. Atkins

Subjects
Oncology, medicine.medical_specialty, Combination therapy, medicine.drug_class, Cost effectiveness, Cost-Benefit Analysis, Immunology, Checkmate, Tyrosine-kinase inhibitor, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Renal cell carcinoma, Internal medicine, Humans, Immunology and Allergy, Medicine, Computer Simulation, 030212 general & internal medicine, Carcinoma, Renal Cell, Neoplasm Staging, Poor risk, business.industry, Antineoplastic Protocols, medicine.disease, Ipilimumab, Survival Analysis, Kidney Neoplasms, Models, Economic, Nivolumab, Treatment Outcome, 030220 oncology & carcinogenesis, Drug Therapy, Combination, Quality-Adjusted Life Years, business
Abstract

Aim: To assess the cost–effectiveness of treatment sequences for patients with intermediate- to poor-risk advanced renal cell carcinoma. Patients & methods: A discrete event simulation model was developed to estimate patients’ lifetime costs and survival. Efficacy inputs were derived from the CheckMate 214 and CheckMate 025 studies and network meta-analyses. Safety and cost data were obtained from the published literature. Results: The estimated average quality-adjusted life-years (QALYs) gained was the highest on nivolumab + ipilimumab-initiated sequences (3.6–5.3 QALYs) versus tyrosine kinase inhibitor (TKI)-initiated sequences (2.1–3.7 QALYs). Incremental cost per QALY gained for nivolumab + ipilimumab-initiated sequences was below the willingness-to-pay threshold of $150,000 versus other sequences. Conclusion: Immuno-oncology combination therapy followed by TKIs is cost-effective versus TKI sequences followed by immuno-oncology or sequencing TKIs.

Published
2020
Full Text
View/download PDF

32. Microinsurance: A short history

Author

David M. Dror

Subjects
Actuarial science, Public Administration, Sociology and Political Science, Microinsurance, Economics, Econometrics and Finance (miscellaneous), Business
Published
2019
Full Text
View/download PDF

33. Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial

Author

Daniel J. George, Joel Picus, Olwen Hahn, Darren R. Feldman, Shaker R. Dakhil, Meghara K. Walsh, Susan Halabi, Colin Hessel, Michael J. Morris, Toni K. Choueiri, Christian Scheffold, M. Dror Michaelson, Eric J. Small, and Milan Mangeshkar

Subjects
Male, Oncology, Cancer Research, medicine.medical_specialty, Cabozantinib, Pyridines, Bone Neoplasms, Subgroup analysis, urologic and male genital diseases, law.invention, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Randomized controlled trial, law, Renal cell carcinoma, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Sunitinib, medicine, Carcinoma, Humans, Anilides, 030212 general & internal medicine, Carcinoma, Renal Cell, Survival rate, Aged, Retrospective Studies, business.industry, Prognosis, medicine.disease, Kidney Neoplasms, 3. Good health, Survival Rate, Clinical trial, chemistry, 030220 oncology & carcinogenesis, Female, Brief Communications, business, Follow-Up Studies, medicine.drug
Abstract

The phase II CABOSUN trial compared cabozantinib with sunitinib as initial treatment in patients with advanced renal cell carcinoma of intermediate or poor risk. This article presents subgroup analyses by baseline patient characteristics., Cabozantinib treatment prolonged progression‐free survival (PFS) and improved objective response rate (ORR) compared with sunitinib in patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria in the phase II CABOSUN trial (NCT01835158). In the trial, 157 patients were randomized 1:1 to receive cabozantinib or sunitinib, stratified by IMDC risk group and presence of bone metastases. Here, PFS and ORR, both determined by independent radiology committee (IRC), were analyzed by subgroups of baseline characteristics. Cabozantinib treatment was generally associated with improved PFS and ORR versus sunitinib across subgroups, including in groups defined by IMDC risk group, bone metastases, age, and tumor burden. Clinical trial identification number. NCT01835158.

Published
2019
Full Text
View/download PDF

37. An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma

Author

Bonne J. Adams, David F. McDermott, Charles P. Theuer, Zhenhua Yuan, Manoj A. Jivani, Guru Sonpavde, Ben K. Seon, Yingmiao Liu, Edwin M. Posadas, M. Dror Michaelson, Andrew B. Nixon, Toni K. Choueiri, and Meghara K. Walsh

Subjects
0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, education.field_of_study, business.industry, Population, Endoglin, medicine.disease, Axitinib, 03 medical and health sciences, Clear cell renal cell carcinoma, 030104 developmental biology, 0302 clinical medicine, Pharmacokinetics, Renal cell carcinoma, 030220 oncology & carcinogenesis, Internal medicine, Toxicity, medicine, Adverse effect, business, education, medicine.drug
Abstract

Background TRC105 is an IgG1 endoglin monoclonal antibody that potentiates VEGF inhibitors in preclinical models. We assessed safety, pharmacokinetics, and antitumor activity of TRC105 in combination with axitinib in patients with metastatic renal cell carcinoma (mRCC). Subjects, Materials, and Methods Heavily pretreated mRCC patients were treated with TRC105 weekly (8 mg/kg and then 10 mg/kg) in combination with axitinib (initially at 5 mg b.i.d. and then escalated per patient tolerance to a maximum of 10 mg b.i.d.) until disease progression or unacceptable toxicity using a standard 3 + 3 phase I design. Results Eighteen patients (median number of prior therapies = 3) were treated. TRC105 dose escalation proceeded to 10 mg/kg weekly without dose-limiting toxicity. Adverse event characteristics of each drug were not increased in frequency or severity when the two drugs were administered concurrently. TRC105 and axitinib demonstrated preliminary evidence of activity, including partial responses (PR) by RECIST in 29% of patients, and median progression-free survival (11.3 months). None of the patients with PR had PR to prior first-line treatment. Lower baseline levels of osteopontin and higher baseline levels of TGF-β receptor 3 correlated with overall response rate. Conclusion TRC105 at 8 and 10 mg/kg weekly was well tolerated in combination with axitinib, with encouraging evidence of activity in patients with mRCC. A multicenter, randomized phase II trial of TRC105 and axitinib has recently completed enrollment (NCT01806064). Implications for Practice TRC105 is a monoclonal antibody to endoglin (CD105), a receptor densely expressed on proliferating endothelial cells and also on renal cancer stem cells that is implicated as a mediator of resistance to inhibitors of the VEGF pathway. In this Phase I trial, TRC105 combined safely with axitinib at the recommended single agent doses of each drug in patients with renal cell carcinoma. The combination demonstrated durable activity in a VEGF inhibitor-refractory population and modulated several angiogenic biomarkers. A randomized Phase II trial testing TRC105 in combination with axitinib in clear cell renal cell carcinoma has completed accrual.

Published
2018
Full Text
View/download PDF

41. Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma?

Author

David F. McDermott, M. Dror Michaelson, and Xin Gao

Subjects
Cancer Research, Immune checkpoint inhibitors, Angiogenesis Inhibitors, urologic and male genital diseases, Models, Biological, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Renal cell carcinoma, Antiangiogenic agents, Commentaries, Antineoplastic Combined Chemotherapy Protocols, Humans, Medicine, 030212 general & internal medicine, Clinical efficacy, Carcinoma, Renal Cell, Randomized Controlled Trials as Topic, Neovascularization, Pathologic, Antitumor immunity, business.industry, Antiangiogenic therapy, Drug Synergism, Prognosis, medicine.disease, Kidney Neoplasms, female genital diseases and pregnancy complications, Clinical Trials, Phase III as Topic, Oncology, 030220 oncology & carcinogenesis, Cancer research, Immunotherapy, business
Abstract

Combination therapies involving antiangiogenic agents plus immune checkpoint inhibitors have recently demonstrated clinical efficacy in advanced renal cell carcinoma (RCC). This commentary summarizes the clinical advances and reviews the potential implications for RCC and other advanced solid tumors.

Published
2019
Full Text
View/download PDF

43. Phase II Study of Cabozantinib in Patients With Bone Metastasis.

Author

Choy, Edwin, Cote, Gregory M, Michaelson, M Dror, Wirth, Lori, Gainor, Justin F, Muzikansky, Alona, Sequist, Lecia V, Sullivan, Ryan J, Fidias, Panagiotis M, Shaw, Alice, and Heist, Rebecca S

Subjects
DRUG efficacy, COLLAGEN, CLINICAL trials, ORAL drug administration, ANTINEOPLASTIC agents, BONE tumors, CANCER patients, BONE metastasis, BONE remodeling, PATIENT safety, SARCOMA, PEPTIDES
Abstract

Bone metastases are often difficult to manage as they can be symptomatic and skeletal-related events (SREs) can contribute to significant morbidity and declines in performance status. We sought to identify a novel medical treatment for bone metastasis by testing the safety and efficacy of cabozantinib in patients with bone metastasis arising from non-breast, non-prostate, malignant solid tumors. Patients were administered cabozantinib as an oral drug starting at 60 mg per day and radiologic measurements were performed at baseline and every 8 weeks. Thirty-seven patients were enrolled. No SREs were observed throughout the study. Twenty patients had disease measurable by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Four of 20 had a partial response by RECIST. An additional 12 patients had some decrease in tumor burden with nine of these having a decrease in tumor burden of at least 10% by RECIST. Six of the patients with at least a minor response had sarcoma. Sixteen patients had biomarkers of bone turnover measured before and after treatment. Most of these patients demonstrated decrease in urine and serum N-telopeptide and serum C-telopeptide. However, these changes in biomarkers of bone turnover did not correlate with radiographic changes measured by RECIST. This study demonstrates clinical activity and safety for cabozantinib in heavily pretreated patients with bone metastasis and shows activity for cabozantinib in patients with metastatic sarcoma. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

48. Sunitinib in Patients With Metastatic Renal Cell Carcinoma

Author

Motzer, Robert J., Rini, Brian I., Bukowski, Ronald M., Curti, Brendan D., George, Daniel J., Hudes, Gary R., Redman, Bruce G., Margolin, Kim A., Merchan, Jaime R., Wilding, George, Ginsberg, Michelle S., Bacik, Jennifer, Kim, Sindy T., Baum, Charles M., and Michaelson, M. Dror

Published
2006

49. Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma

Author

Motzer, Robert J., Michaelson, M Dror, Redman, Bruce G., Hudes, Gary R., Wilding, George, Figlin, Robert A., Ginsberg, Michelle S., Kim, Sindy T., Baum, Charles M., DePrimo, Samuel E., Li, Jim Z., Bello, Carlo L., Theuer, Charles P., George, Daniel J., and Rini, Brian I.

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results